
|Articles|October 8, 2012
Aimee Tharaldson, PharmD, Discusses the Biosimilar Pathway
Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway and compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy's Educational Conference.
Advertisement
Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy’s Educational Conference. Once more guidance is available from the FDA, there will be more biosimilar approvals, Dr. Tharaldson told the American Journal of Managed Care.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5








































































































































